Dacomitinib Disease Interactions
There are 2 disease interactions with dacomitinib.
Dacomitinib (applies to dacomitinib) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The recommended dose of dacomitinib has not been established for patients with severe renal impairment (CrCl <30 mL/min). Caution is advised if used in these patients. No dose adjustment is recommended for patients with mild or moderate renal impairment.
References
- (2018) "Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group
Dacomitinib (applies to dacomitinib) severe hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The recommended dose of dacomitinib has not been established for patients with severe hepatic impairment (total bilirubin > 3 to 10 × ULN and any AST). Caution is advised if used in these patients. No dose adjustment is recommended in patients with mild or moderate hepatic impairment.
References
- (2018) "Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group
Dacomitinib drug interactions
There are 92 drug interactions with dacomitinib.
More about dacomitinib
- dacomitinib consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: EGFR inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.